|
This is a letter from Patton Boggs regarding a modified timeline for submissions related to environmental monitoring reports, addressed to the Office of Pollution Prevention and Toxics.
|
2004 |
AR226-2743
|
RpbZyOL3ybQeE14J7aMx036kv |
21 |
|
The document reports on a study conducted by E.I. du Pont de Nemours and Company that evaluated the acute toxicity of a substance identified as H-24750 (99.6% purity) to Daphnia magna in a 48-hour static test.
|
2004 |
AR226-2814
|
0Jy540zxVDbmznBKwJJ79z9mJ |
8 |
|
The document details a peer review of ovarian slides from a two-year oral toxicity-oncogenicity study in rats, conducted by E. I. du Pont de Nemours and Company, focusing on proliferative lesions and diagnostic criteria related to the evaluation of the effects of a perfluorinated compound.
|
2004 |
AR226-2816
|
Zpbqa6DEjxjyvw81BgBN2aq0 |
15 |
|
The document is a study report by E.I. du Pont de Nemours and Company evaluating the interference of certain test substances, including PFOA, in the analysis of rat serum lipids, completed on October 13, 2004.
|
2004 |
AR226-2817
|
oMerj9r9DMZ4eBEXz04XRBayo |
29 |
|
The document is a dossier prepared by the Swedish Chemicals Inspectorate and the Swedish EPA in August 2004, detailing the preliminary risk profile of perfluorooctane sulfonate (PFOS) in support of its nomination to the UN-ECE LRTAP Protocol and the Stockholm Convention, highlighting its chemical identity, environmental release, and potential risks.
|
2004 |
AR226-3621
|
7MDZv075G9nqybvZa6bEz1zDe |
45 |
|
The document discusses the thermal degradation behavior of perfluorinated surfactants, specifically comparing the thermal stability of 3M's fluorosurfactant "C8" (FC-143) and another unspecified telomer product at 400°C, revealing that "C8" is unstable above 130°C.
|
2004 |
AR226-2678
|
KRDMzaQmm8v3beg3bJ942Yg0Q |
5 |
|
The document presents blood serum PFOA levels among mechanics at various DuPont facilities, including Charleston, WV, and Deepwater, NJ, with findings indicating an average PFOA concentration of 18.01 ppb among sampled individuals.
|
2004 |
AR226-3652
|
rZX5Vo33rVymEV0X6aNYpnK7 |
10 |
|
The Michigan Department of Community Health issued an advisory regarding acute respiratory illnesses linked to aerosolized waterproofing products, specifically identifying Jobsite Heavy Duty Bootmate and Rocky Boot Weather and Stain Protector, both produced by Assured Packaging, which have resulted in numerous hospitalizations and at least three pet fatalities.
|
2004 |
AR226-3703
|
1gpQ67zvgvq1p17oLJMqNdy1E |
2 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3576
|
O3g9N1Y3zLgJB4mxvvN9o6Raj |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including various perfluorinated compounds, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for heptafluorobutyric acid (PFBA) was excluded due to instability issues.
|
2004 |
AR226-3578
|
RjRRywRzEre40D5ya3Y6ZKeOz |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of 36 lots of commercially available human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, while noting that data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3580
|
DD485RK9pkJwgGME4qw5Ezkpo |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six lots of commercially available human serum for sixteen different fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3576
|
NNkqYpgbjJ9mbvQw35d2aE3QQ |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six commercial lots of human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3578
|
by1Y8qYroRZNnNo5KrxyMVJyk |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six commercial lots of human serum for sixteen endogenous fluorochemicals, including a note that data for heptafluorobutyric acid (PFBA) will not be included due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3580
|
3QEgaG7q6rv2Zv5R69wr4qVen |
19 |
|
This document consists of multiple pages marked as "DuPont Confidential," but contains no analytical content due to extensive sanitization and redaction.
|
2004 |
AR226-3324
|
KJ1z1wJJq9OaaBJajnjnm75e6 |
7 |
|
This document appears to be a summary related to the supply chain chemistry of telomers produced by DuPont for surface protection solutions, dated May 6, 2004, but contains no analytical content due to sanitization.
|
2004 |
AR226-3327
|
kmDX79408R3972pJ3N4XxoX6B |
30 |
|
The document discusses DuPont's manufacturing processes for telomer-based products, revealing the presence of trace PFOA impurities as unintended byproducts.
|
2004 |
AR226-3329
|
D6xVRwgr2XaGvMyqj4mQbmE4 |
7 |
|
The document outlines DuPont's objectives to develop a baseline understanding of the impurity profile of their Telomer products and intermediates used in manufacturing surface protection solutions, including various applications such as textiles and fire-fighting foams, while ensuring confidentiality regarding proprietary information.
|
2004 |
AR226-3328
|
MGvyX3xwMgqQJjRMb53oqDXpz |
68 |
|
The document summarizes presentations from the Society of Environmental Toxicology & Chemistry regarding DuPont's research on the biodegradation pathways and transformation products of perfluorooctyl ethanol (8-2 Telomer B Alcohol) and the soil-water partitioning of fluorotelomer intermediates used in manufacturing fluorotelomer-based polymers.
|
2004 |
AR226-3352
|
oMk9OB87N6vkrG8No9VrKb5bR |
4 |
|
The document discusses the atmospheric persistence and degradation products of fluorotelomer alcohols (FTOHs) and long-chain perfluorinated carboxylic acids (PFCAs), detailing experimental methodologies for measuring reaction rate constants involving various fluorinated compounds.
|
2004 |
AR226-3360
|
Yr8643xvD2peOzJRwq1njZeNO |
21 |
|
This manuscript reports that textiles and paper treated with a fluorotelomer-based acrylic polymer do not produce detectable amounts of perfluorooctanoic acid (PFOA) when subjected to typical municipal incineration conditions, indicating they are not a significant source of PFOA in the environment.
|
2004 |
AR226-3362
|
93Nxb4zOBqJDOooMDka9ggQxp |
58 |
|
The document summarizes presentations by DuPont at the Society of Environmental Toxicology & Chemistry North American World Congress regarding the biodegradation and environmental fate of fluorotelomer substances, specifically focusing on the biotransformation of 14C-labeled 8-2 Telomer B alcohol and its potential microbial defluorination pathways.
|
2004 |
AR226-3363
|
98Gn3w9De8wbxgOaOMoaaNjq |
3 |
|
The document reports on a 90-day subchronic toxicity study of 8-2 Telomer B Alcohol conducted by DuPont and other collaborators, revealing that while no mortality occurred, high doses led to increased liver weight, hepatic necrosis in males, and chronic nephrotoxicity in females, along with dental and plasma fluorine level changes.
|
2004 |
AR226-3392
|
vB5OZ4vamkMBnDY8Z9BYKzgJR |
1 |
|
The document presents pilot results from a toxicokinetics study on PFOA conducted by DuPont Haskell Laboratory, indicating that an oral dose of 125 mg/kg resulted in significant absorption and the identification of various metabolites in rat subjects.
|
2004 |
AR226-3394
|
jL6MOrRDg9RjBa3RvZpKEeEk |
5 |
|
DuPont submitted occupational blood monitoring summary documents to the EPA in response to a request dated November 4, 2004, regarding PFOA, asserting that the information does not trigger reporting obligations under TSCA section 8(e).
|
2004 |
AR226-3396
|
dQ75r83BEGNGZBzMVLvmRzQ1B |
16 |
|
The document is a letter from DuPont's attorney, Anthony F. Cavanaugh, to the EPA's Mary Dominiak, clarifying clerical errors in the submission of six boxes of documents related to C-8 (PFOA) air and water monitoring data.
|
2004 |
AR226-3550
|
pp75ZxRmpBrz8EGLEBkEygGpj |
43 |
|
This is a cover letter addressed to Ms. Mary Dominiak at the EPA's Document Control Office, dated November 19, 2004, indicating that the enclosed materials contain TSCA Confidential Business Information.
|
2004 |
AR226-3551
|
99v0ed8GXj3qyg7D15ygkz1J5 |
3 |
|
This is a letter from Patton Boggs dated December 10, 2004, addressed to Peter D. Robertson, regarding the submission of documents related to occupational blood monitoring as requested by the EPA.
|
2004 |
AR226-3553
|
b5xnyx2Vj411ankp4yLvZKQvD |
10 |
|
DuPont submitted a letter to the EPA detailing their voluntary response to a request for information regarding PFOA, including a modified timeline for submitting toxicology, pharmacokinetics, and monitoring reports.
|
2004 |
AR226-3552
|
3Q9MN2xw6Qzzo2pOX54d9pZg0 |
21 |
|
DuPont submitted additional epidemiology and industrial hygiene air monitoring data to the EPA in response to a request dated November 4, 2004, indicating their ongoing cooperation and belief that the information does not trigger reporting obligations under TSCA section 8.
|
2004 |
AR226-3555
|
YGw7bZKVrV6ZZ55Od20VJOMvy |
15 |
|
This is a letterhead cover page from Patton Boggs, with no analytical content retained in the OCR.
|
2004 |
AR226-3556
|
N7279oyO2w34BkDprb8n6Ynw |
4 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including a focus on PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, while noting that data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3576
|
YjZzOz8bJO6dv4M2w1OEpkBJO |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six commercial lots of human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3578
|
dYR6oKNJkE9rdd1MVKnyegV80 |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six lots of commercially available human serum for sixteen endogenous fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3580
|
0JJ8JGGq3aQ6YqE2V39k2Nrvd |
19 |
|
The document is an analytical report from Severn Trent Laboratories for Weston Solutions, Inc., detailing the testing of soil samples related to a confidential investigation into perfluorinated compounds, specifically under job number 232881.
|
2004 |
AR226-3828
|
8R0NBrnn4Ov1xZJMj2Kv2RN5e |
38 |
|
This document is an analytical report from Severn Trent Laboratories for Weston Solutions, detailing the testing of soil samples related to a confidential investigation in Decatur, with job number 232883.
|
2004 |
AR226-3828
|
rx7mGQ26BVbEM9w6vLpR363ra |
56 |
|
3M submitted a supplemental report to the EPA regarding a pharmacokinetic study on ammonium perfluorooctanoate (PFOA) in rats, following previous communications about related reproductive studies.
|
2004 |
AR226-1550
|
DDgRMBzvyd5wYXQBaL55nzxnM |
1 |
|
3M submitted a supplemental report to the EPA detailing results from a study on ammonium perfluorooctanoate (PFOA) regarding its effects on plasma concentration in post-weaning rats following oral gavage.
|
2004 |
AR226-1552
|
RJ6J9eOGy2g1Lvvv3yQqBKKzX |
1 |
|
3M submitted a supplemental report to the EPA detailing a pharmacokinetic study that found perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS) in rats, with maximum PFOS concentration observed in the liver on day 4 post-dose.
|
2004 |
AR226-1694
|
ByVvDBNOBXmJQV9VGEM431D94 |
1 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP regarding a PFOA human health effects study, specifically addressing cancer data related to PFOA.
|
2004 |
AR226-1714
|
6R2vYY98bVJ4deOag9zQvRwR1 |
1 |
|
This document is an analytical report from Centre Analytical Laboratories detailing the fluorochemical characterization of water and sediment samples, specifically analyzing perfluorooctane sulfonate (PFOS), perfluorooctane sulfonamide (PFOSA), and perfluorooctanoate (POAA) from 3M's Project E00-2003 in Port St. Lucie, Florida
|
2003 |
AR226-0979
|
KJnM5OzBR9BME8BGj4m6G25RX |
9 |
|
This document is an analytical report from Centre Analytical Laboratories detailing the characterization of fluorochemicals, specifically PFOS, PFOSA, and POAA, in water, leachate, sludge, and sediment samples collected from Port St. Lucie, Florida, as part of a project requested by 3M Environmental Laboratory.
|
2003 |
AR226-1030
|
evpd7wLm5wqjQaDLBgLOzbZZq |
65 |
|
This document is an analytical report from Centre Analytical Laboratories detailing the fluorochemical characterization of drinking water, surface water, sediment, and leachate samples from Port St. Lucie, Florida, specifically analyzing for perfluorooctane sulfonate (PFOS), perfluorooctane sulfonamide (PFOSA), and perfluorooctanoate (POAA) using
|
2003 |
AR226-1030
|
xdbRyjaMG2n6Bm71J0wkZN99m |
65 |
|
This analytical report from Centre Analytical Laboratories details the characterization of water and sediment samples collected from Port St. Lucie, Florida, for 3M Project E00-2003, specifically analyzing for perfluorooctane sulfonate (PFOS), perfluorooctane sulfonamide (PFOSA), and perfluorooctanoate (POAA) using liquid chromatography
|
2003 |
AR226-0676
|
Emx8M3BkDk38mErkpJrD2oa7R |
9 |
|
The document is a letter from DuPont's Stephen H. Korzeniowski to EPA's Mary Dominiak, submitting information about the Telomer manufacturing process related to the potential release of PFOA as part of the Telomer Research Program's voluntary commitment.
|
2003 |
AR226-1265
|
MJzpKMp4KGqXgzd0d4BKDxd5k |
1 |
|
The document outlines the Telomer Research Program, detailing the manufacturing processes for telomer-based fluorochemicals, specifically noting that PFOA is not used or added in these processes and that emissions are expected to be very low.
|
2003 |
AR226-1266
|
7MqMYvzzJL27znRyemqjyG2qa |
6 |
|
Dyneon LLC submitted a letter to the EPA detailing their compliance with the PFOA Users Letter of Intent by providing a list of their manufacturing site in Decatur, Alabama, where they produce fluoropolymers using APFO (CAS No. 3825-26-1).
|
2003 |
AR226-1270
|
nmRGVzn1YNQgdwkn2eq6XZEdw |
1 |
|
The document is a communication from Katie D. Smythe of the Telomer Research Program to Mary F. Dominiak at the EPA, providing draft study plans for analyzing PFOA in telomer-based products and treated articles, and requesting feedback by February 28.
|
2003 |
AR226-1271
|
k9Dk59VxbJ2x4g48RKxNVEejn |
1 |
|
The document outlines a proposed study plan for analyzing PFOA levels in 11 different telomer-based products using LC/MS/MS methodology, with the aim of determining the presence and concentration of PFOA by May 2003.
|
2003 |
AR226-1272
|
kDjnZwxzD644JaYOa9XBZ9rRJ |
2 |
|
The document outlines a proposed study plan for analyzing PFOA levels in 11 articles treated with telomer-based products, using LC/MS/MS methodology to determine the presence and concentration of PFOA, with analyses to be completed by May 2003.
|
2003 |
AR226-1273
|
emjNGwQG41LXR2vx0QDmqQYXm |
4 |
|
The document outlines a preliminary study for the Telomer Research Program, detailing the sampling and analysis procedures for extracting PFOA from treated and untreated carpet and textile matrices at various concentrations.
|
2003 |
AR226-1274
|
g2ZRJQNxMjw5V95ovJ8kYLjde |
5 |
|
The document is a submission of the final study report on perfluorinated compounds to the EPA's AR-226 administrative record, specifically addressing findings related to the Telomer Research Program.
|
2003 |
AR226-1275
|
JrapzDNdVaomjaj68kE093aL2 |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the U.S. EPA, providing two journal articles for inclusion in Administrative Record 226, which focus on environmental levels of PFOS in Japan and blood levels of PFOA in Japanese individuals.
|
2003 |
AR226-1277
|
8RR7n5xzMM3znpEr5NR8Qbz0a |
1 |
|
This document discusses the first environmental survey of perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in Japan, highlighting their global distribution, environmental persistence, bioaccumulation, and the need for further investigation into their toxicity and environmental impact.
|
2003 |
AR226-1278
|
pmVk6KYD7DxqkYk2aReZjD4Z7 |
4 |
|
This document is a progress report submitted by Katie Smythe on behalf of the Telomer Research Program to the U.S. EPA, detailing Year 1 findings from the University of Toronto's research on fluorotelomer alcohols, with no confidential business information included.
|
2003 |
AR226-1280
|
wgqKwROVx6Q640494x1kL4gNJ |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the EPA, detailing the scope and rationale for the "8-2 Telomer B Alcohol Biodegradation Research" as part of ongoing TRP research activities.
|
2003 |
AR226-1282
|
938VOzQ1Od09LbqKDN552rqRD |
1 |
|
The document is a submission from the Telomer Research Program to the EPA, detailing the scope and rationale for a study on "Analysis of Telomer-Based Products and Telomer-Treated Articles," which is part of their voluntary commitment regarding perfluorinated compounds.
|
2003 |
AR226-1284
|
wgbeOb73aXOzYX6XQvQJoR03 |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the EPA, providing study reports on 8-2 Telomer B Alcohol (CAS# 678-39-7) for inclusion in Administrative Record 226, confirming that none of the attached files contain Confidential Business Information.
|
2003 |
AR226-1286
|
375ozQY7G6yMNd0rqgG9r87qO |
1 |
|
The document outlines the Telomer Research Program's investigation into the potential release of perfluorooctanoic acid (PFOA) from telomer-based products and treated consumer articles, focusing on analyzing PFOA levels in carpets, textiles, and paper to assess human and environmental exposure.
|
2003 |
AR226-1285
|
BpLwkn1v0VX4JKZZN0gw09Do |
4 |
|
The document is a DuPont report detailing the vapor pressure determination of 8-2 Telomer B Alcohol (C8F17CH2CH2OH), conducted under the Telomer Research Program, with the study completed on July 16, 2002, and reported on March 21, 2003.
|
2003 |
AR226-1288
|
wr9D3X7n6BMopeyYJN72GeRNQ |
10 |
|
The document is a submission from the Telomer Research Program to the EPA, providing a list of documents related to telomers, including studies on physical-chemical properties, toxicology, and environmental effects, with a commitment to submit the actual documents by April 15, 2003.
|
2003 |
AR226-1291
|
Rpe4VwojO4XgddGke5nK71zeB |
1 |
|
This document appears to be a summary of available data types related to various perfluoroalkyl substances (PFAS) analyzed under the Telomer Research Program, detailing their physical properties, toxicity, and environmental effects.
|
2003 |
AR226-1292
|
XRB6z68VLZXJOEbyOOK4oJ3gR |
2 |
|
DuPont submitted a letter to the EPA detailing its U.S. sites that use Ammonium Perfluorooctanoate (APFO) to produce fluoropolymers, as part of its commitment following a voluntary action letter dated March 14, 2003.
|
2003 |
AR226-1295
|
omXbNbk0YYB0w2BpXzOjXQOM3 |
2 |
|
This document is a presentation from the Telomer Research Program meeting held on February 3, 2003, detailing information sharing and study reports related to telomer manufacturing and environmental impacts, prepared for the U.S. EPA's OPPT.
|
2003 |
AR226-1299
|
aJ11gqj2pZG3OYo9gOr2GdKrM |
25 |
|
3M Company outlines its ongoing environmental, health, and safety measures regarding perfluorooctanoic acid (PFOA), including past efforts to characterize exposure, conduct research, and plans for future monitoring and data development related to PFOA exposure from its former manufacturing activities.
|
2003 |
AR226-1303
|
6YE2Gd1dj9YO6eGG6XZV4QE6 |
9 |
|
The document is a Letter of Intent from several companies, including Asahi Glass Fluoropolymers USA, Daikin America, and E. I. du Pont de Nemours, to the EPA, outlining their initiatives to assist in the assessment of ammonium perfluorooctanoate (APFO) and ensure its safe use in the manufacture of fluoropolymers.
|
2003 |
AR226-1304
|
5k8Y06axk4DgLLrEbQaoEL7NJ |
26 |
|
The document is a Letter of Intent from members of the Telomer Research Program to the EPA, outlining their commitment to address concerns regarding the potential association of perfluorooctanoic acid (PFOA) with telomer-based products and detailing their evaluation of PFOA exposure from these products.
|
2003 |
AR226-1305
|
pzzy13brwrM49aEk9vnODdod |
20 |
|
This letter reaffirms the commitment of several companies, including DuPont and Daikin America, to assist the EPA in investigating perfluorooctanoic acid (PFOA) and ammonium perfluorooctanoate (APFO), focusing on developing data regarding their health and environmental effects and improving exposure prevention measures.
|
2003 |
AR226-1306
|
4QQZdXLbgmLxg5qX1jLw35Vee |
10 |
|
The document is a report from the Epidemiology Program detailing cancer incidence data from 1959 to 2001 at the DuPont Washington Works site in Parkersburg, West Virginia, comparing observed cancer cases to expected cases using the Standardized Incidence Ratio (SIR).
|
2003 |
AR226-1307
|
Lp2yJJV9Zavo2GGeB6kZDGBeb |
19 |
|
This document is a letter addressing the potential human health threat from releases of PFOA (C-8) from the E.I. duPont de Nemours and Company plant in West Virginia and Ohio, sent to various officials at the U.S. Environmental Protection Agency and the Ohio Environmental Protection Agency.
|
2003 |
AR226-1308
|
x5g4NeXj1wDd1XGra1do447zQ |
2 |
|
The memorandum summarizes a March 5, 2003 meeting between EPA and representatives from 3M, DuPont, and Daikin to discuss perfluorooctanoic acid (PFOA), where industry representatives expressed their views on PFOA risks and outlined their voluntary product stewardship efforts, including commitments to reduce emissions and assess environmental presence.
|
2003 |
AR226-1309
|
ZJoQEpXbXdxJvyvqqmKwD55aY |
2 |
|
The memorandum summarizes a March 14, 2003 meeting between EPA officials and the Environmental Working Group, where concerns were raised about the hazards, exposures, and risks associated with PFOA and PFOS, including their widespread presence in humans and the environment, as well as the potential for telomer alcohols to biodegrade into PFOA.
|
2003 |
AR226-1310
|
KJ4O0ZYY4j2vvLKLOdz9evB36 |
1 |
|
The memorandum discusses the Preliminary Risk Assessment of the developmental toxicity associated with PFOA (Perfluorooctanoic Acid) and its salts, highlighting the use of human and rat serum data for calculating margins of exposure (MOEs) and acknowledging limitations in the available data.
|
2003 |
AR226-1311
|
evxgBQQoy44MVGx9XEoEkx90e |
4 |
|
The document is a submission to the EPA's AR 226 regarding the mechanics of film formation of aqueous film-forming foam (AFFF) fire fighting agents, including attached presentations and papers on fluorosurfactants, in response to an EPA request for information.
|
2003 |
AR226-1312
|
qknDxDzXoKbn1ReMJVOraN8Yk |
1 |
|
The document discusses the properties and effectiveness of fluorinated surfactants, specifically in the context of fire fighting foams, highlighting their thermal and chemical stability, as well as their unique surfactant characteristics due to the perfluorinated chain structure, authored by Martial Pabon from DuPont.
|
2003 |
AR226-1313
|
8598LyoLO6RmOJ26p7335vK8Z |
19 |
|
This is a letterhead cover page from DuPont, with no analytical content retained in the OCR.
|
2003 |
AR226-1316
|
k65dRD75KeeoyDn1ea34yM68O |
1 |
|
The document is a submission from DuPont detailing the 2002 sales and usage data of their telomer-based products in the United States, which includes information on various applications such as carpet, coatings, and firefighting foam, as part of their commitment to the EPA's Telomer Research Program.
|
2003 |
AR226-1317
|
vBomgRQgbOQErdYbL6mBqEr2Y |
2 |
|
3M submitted a supplemental report to the EPA detailing ecotoxicity studies on triphenylbenzyl phosphonium cation/N-methyl perfluorooctanesulfonamide salt (TPBP C8 amide), indicating acute toxicity to zebra-fish, Daphnia magna, and algae, while asserting that environmental exposure is unlikely due to its use in fluoroelastomer production.
|
2003 |
AR226-1319
|
9154Zd4o0oN740Vevro8VwEN5 |
2 |
|
The document is a letter from the EPA to DuPont regarding TSCA 8(e) reporting requirements for PFOA, highlighting concerns raised by an Environmental Working Group report about PFOA exposure among female workers and related health effects, including findings of PFOA in umbilical cord blood and potential birth defects.
|
2003 |
AR226-1318
|
M4G8B2YvrdKr7K23KVdkwpXM |
6 |
|
3M submitted a substantial risk notice to the EPA regarding an acute eye irritation study on phosphonium, triphenyl(phenylmethyl)-, salt with 1,1,2,2,3,3,4,4,4-nonafluoro-N-methyl-l-butanesulfonamide (CAS 332350-93-3), which indicated ocular corrosion and nec
|
2003 |
AR226-1322
|
a4RbwzvGbXkaQ7Gk4XGbzkr0a |
2 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding the fluorochemical alcohol 1-butanesulfonamide, 1,1,2,2,3,3,4,4,4-nonafluoro-N-(2-hydroxyethyl)-N-methyl (CAS 34454-97-2), indicating that a subchronic oral
|
2003 |
AR226-1324
|
EqvZaYryvMaY6YGm5v7NggyVx |
2 |
|
This letter from DuPont's Corporate Counsel addresses the EPA's inquiry regarding the reportability of PFOA-related health and environmental data under TSCA Section 8(e), asserting that the information does not indicate a "substantial risk" and therefore does not require reporting.
|
2003 |
AR226-1327
|
OJzvqnZ1N9omN6RNpKk1koLXL |
10 |
|
This document is a submission from 3M to the EPA regarding the final reports of three ecotoxicity studies on triphenylbenzyl phosphonium cation/N-methyl perfluorooctanesulfonamide salt (TPBP C8 amide), indicating that the results are consistent with previously reported information.
|
2003 |
AR226-1334
|
44ZpxEX5B4nGvBGDYLBoKkqDR |
1 |
|
This is a document submission cover letter from Katie Smythe on behalf of the Telonrer Research Program, indicating the submission of materials related to the TRP.
|
2003 |
AR226-1338
|
5K3Lxr4DN511rj73NLv7v4nJ |
1 |
|
Asahi Glass Co., Ltd. submitted information to the EPA regarding their telomer-based products, including both polymeric and non-polymeric types, as part of their regulatory compliance efforts for products exported to the United States.
|
2003 |
AR226-1326
|
npndmo1gLXvbrwMLovxqgLDq6 |
2 |
|
This is a document submission from the Telomer Research Program, prepared by Katie Smythe, regarding unspecified analytical content.
|
2003 |
AR226-1343
|
3JB1d8qB6D75B6wwvrmnKdXmD |
1 |
|
The document reports on a study conducted by DuPont on the acute oral toxicity of 8-2 Telomer B Alcohol, indicating no clinical signs of toxicity were observed at the tested doses.
|
2003 |
AR226-1344
|
Ozapq538gXB3NwDwZopypaJ5L |
1 |
|
3M is submitting additional data and studies on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA as part of their ongoing dialogue regarding perfluorochemicals, including a redacted Protein Binding Study report and an updated bibliography of relevant literature.
|
2003 |
AR226-1349
|
XRYzg8OjdKdnB04EpaRRZbL6B |
9 |
|
The final report from 3M Company details a medical surveillance program conducted in December 2002, which analyzed serum concentrations of perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) among 38 employees, revealing that 11 participants had PFOA levels exceeding the biological limit value of 5 ppm, while PFOS levels
|
2003 |
AR226-1352
|
Rjj4k2L0nO8B148EbEOq5q6eV |
13 |
|
The document is a final report from 3M Company assessing the relationship between serum levels of perfluorooctanoate (PFOA) and lipid, hepatic, and thyroid function among its production workforce, establishing a biological limit value of 5 ppm for PFOA to indicate a level not expected to pose significant health risks.
|
2003 |
AR226-1351
|
G627nL72N37X1NynXkQwo2x1v |
41 |
|
The document is a final report from 3M Company detailing a study on serum concentrations of fluorochemicals, including PFOS and PFOA, among Decatur employees, finding that while serum PFOS concentrations remained stable, PFOA levels showed a decline, with all measured concentrations below the biological limit value for PFOA.
|
2003 |
AR226-1353
|
x1od8GNOgywbkJ7gyp23dxwmQ |
20 |
|
The document is a final report on a combined repeated dose toxicity study of test substance T 7599.7, which includes reproduction and developmental toxicity screening, conducted on male and female rats.
|
2003 |
AR226-1325
|
X7qR337K2X5YdgxzGqkrpqBky |
491 |
|
The document is an order from the Circuit Court of Wood County, West Virginia, granting class certification for a lawsuit against E.I. duPont de Nemours and Company regarding contamination of drinking water with ammonium perfluorooctanoate (C-8), a perfluorinated compound, due to releases from DuPont's Washington Works plant.
|
2003 |
AR226-1176
|
Rawx7jGDpKKgnvdQOzgGBOaY8 |
29 |
|
This document reports on a pharmacokinetic study of potassium perfluorooctanesulfonate (PFOS) in cynomolgus monkeys, detailing the serum and urinary excretion patterns following a single intravenous dose, with findings indicating differences in serum concentrations between male and female monkeys over time.
|
2003 |
AR226-1356
|
QMvEvvV5GgX6NXZp5dyRzY845 |
58 |
|
This is a final report from Covance Laboratories (Study 22900-0-4090ECD) on a Salmonella-Escherichia coli mammalian microsome reverse mutation assay for purified 8-2 alcohol, sponsored by the Telomer Research Program Consortium.
|
2003 |
AR226-1197
|
QJaZL8yp86on5E43OwyYOqzL |
38 |
|
3M submitted data on perfluorooctane sulfonates, including results from bacterial mutation and chromosome aberration tests, to the EPA as part of their ongoing dialogue regarding fluorochemicals.
|
2003 |
AR226-1199
|
dDq8Y5EKjgKYOOrgxpbammjN6 |
1 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding preliminary findings from a 28-day oral toxicity study in rats on the chemical intermediate 1-Butanesulfonylfluoride, l,l,2,2,3,3,4,4-octafluoro-4-[(trifluoroethenyl)oxy] (CAS:
|
2003 |
AR226-1202
|
VN2eBxBppe8v5D3jbwO2xVOg |
2 |
|
DuPont submitted a study report on commercially available cookware to the EPA for inclusion in Administrative Record 226, detailing previously presented comments to the Agency.
|
2003 |
AR226-1203
|
NGxn4VYO6D3aZ1djwa2kqeemE |
1 |
|
3M submitted a supplemental report to the EPA detailing new findings from a study on perfluorooctane sulfonate (PFOS) that indicated a statistically significant effect on mean pup body weight at a maternal treatment level of 0.4 mg/kg/day, with a defined dose-response relationship.
|
2003 |
AR226-1205
|
bamKpyMnp78XNjwXzadn541y0 |
1 |
|
The document reports on an analytical study conducted by SCION ICT to determine the presence of perfluorooctanoic acid (PFOA) on the surface of commercial frying pans coated with fluoropolymer, finding no detectable levels of PFOA in the water extract.
|
2003 |
AR226-1204
|
bBywnK81pdpQz1aaob8MbXowO |
21 |